What Is a 503A Pharmacy? A Provider's Guide to 503A vs. 503B Compounding
Short answer: A 503A pharmacy is a state-licensed pharmacy (or federal facility) that compounds drugs for an identified individual patient based on a valid prescription, under section 503A of the Federal Food, Drug, and Cosmetic Act (FD&C Act), codified at 21 U.S.C. § 353a. State boards of pharmacy are its primary day-to-day regulators. A 503B outsourcing facility is a different, voluntary category: it registers with FDA, must follow current good manufacturing practice (CGMP), is inspected by FDA on a risk-based schedule, and may supply office stock that isn't tied to a named patient (FDA).
If your practice, med spa, or telehealth clinic works with compounded products, including compounded peptides, knowing which category your pharmacy partner falls into tells you how orders have to be written, who oversees quality, and what documentation you should expect. This guide walks through both pathways using the statute and FDA's own explanations.
What is a 503A compounding pharmacy?
Section 503A describes the conditions under which a compounded human drug is exempt from three parts of the FD&C Act: FDA pre-market approval, CGMP requirements, and labeling with "adequate directions for use" (FDA). Those exemptions only apply if every condition in the statute is met.
Who can compound under 503A
The statute covers compounding by:
- a licensed pharmacist in a state-licensed pharmacy or a federal facility, or
- a licensed physician,
on a prescription order for an individual patient written by "a licensed physician or other licensed practitioner authorized by State law to prescribe drugs" (21 U.S.C. § 353a(a)).
The patient-specific prescription requirement
The defining feature of 503A is that compounding is tied to an identified individual patient and a valid prescription order. The law allows limited anticipatory compounding, meaning small quantities made before a prescription arrives, only when it's based on a history of receiving valid prescriptions within an established relationship between the pharmacist or physician and the patient or prescriber (21 U.S.C. § 353a(a)(2)). In practice, that means a 503A pharmacy generally isn't a source of non-patient-specific "office stock."
Ingredient rules: the bulk drug substance conditions
A 503A compounder may only use bulk drug substances (active ingredients) that meet one of three conditions (FDA):
- They comply with an applicable USP or NF monograph, if one exists, and the USP chapter on pharmacy compounding;
- If no monograph exists, they are components of FDA-approved drug products; or
- If neither applies, they appear on FDA's 503A bulks list.
On top of that, every bulk drug substance must be manufactured by an FDA-registered establishment and be accompanied by a valid certificate of analysis (COA) (21 U.S.C. § 353a(b)(1)(A)). FDA's own advice to compounders is to "know your bulks supplier."
Other 503A limits worth knowing
- No "essentially copies." A 503A compounder may not regularly or in inordinate amounts compound products that are essentially copies of a commercially available drug. A change made for an identified patient that the prescriber determines produces a significant difference for that patient doesn't count as a copy (21 U.S.C. § 353a(b)(1)(D), (b)(2)).
- Withdrawn and "demonstrably difficult" products. Products on FDA's withdrawn-for-safety-or-effectiveness list can't be compounded, nor can products FDA identifies by regulation as demonstrably difficult to compound.
- Interstate distribution. In a state that hasn't signed FDA's standard memorandum of understanding (MOU), out-of-state distribution is capped at 5% of total prescription orders dispensed or distributed (21 U.S.C. § 353a(b)(3)(B)).
- Reconstitution per labeling isn't compounding. The statute says "compounding" doesn't include mixing or reconstituting done according to the manufacturer's approved labeling (21 U.S.C. § 353a(e)).
What is a 503B outsourcing facility?
The Drug Quality and Security Act (DQSA), enacted November 27, 2013, after the 2012 fungal meningitis outbreak, added section 503B to the FD&C Act (FDA). Under 503B, an outsourcing facility is a facility at one geographic location that compounds sterile drugs, has elected to register with FDA, and complies with all of 503B's requirements (FDA).
Outsourcing facilities:
- must comply with CGMP requirements;
- are inspected by FDA according to a risk-based schedule;
- must report adverse events and report to FDA the drugs they compounded, at initial registration and every June and December (FDA).
FDA keeps a public list of registered outsourcing facilities. Products a 503B facility distributes without a patient-specific prescription must be labeled "Office Use Only" (21 U.S.C. § 353b).
Difference between 503A and 503B compounding pharmacies
| 503A compounding pharmacy | 503B outsourcing facility | |
|---|---|---|
| Statute | FD&C Act § 503A (21 U.S.C. § 353a) | FD&C Act § 503B (21 U.S.C. § 353b) |
| Who | Licensed pharmacist in a state-licensed pharmacy or federal facility, or a licensed physician | Facility that has voluntarily registered with FDA as an outsourcing facility |
| Orders | Patient-specific prescriptions (plus limited anticipatory compounding) | Patient-specific prescriptions or provider orders not for an identified patient (e.g., office stock) |
| Quality standard | USP compounding chapters and state rules; not subject to CGMP | Subject to CGMP |
| Primary oversight | State boards of pharmacy (FDA can do surveillance and for-cause inspections) | FDA, risk-based inspection schedule |
| FDA reporting | No routine product reporting | Adverse event and semiannual product reporting |
Sources: FDA, Compounding Laws; FDA, Compounding Q&A.
One point applies to both: compounded drugs aren't FDA-approved, which means FDA doesn't review them for safety, effectiveness, or quality before they reach patients (FDA). Federal rules on insanitary conditions apply in every compounding setting.
503A compounding pharmacy peptides: what providers should check
Peptides go through the same 503A framework as any other active ingredient, so the bulk substance rules above are where most of the practical questions come from.
Check the substance's status
Many peptides have no USP monograph and aren't components of an FDA-approved drug. For those, eligibility depends on the 503A bulks list and FDA's interim policy for nominated substances. Under that policy, FDA sorts nominated substances into Category 1 (may be eligible, under evaluation), Category 2 (significant safety risks identified), and Category 3 (insufficient supporting information) (FDA). FDA says it doesn't intend to place substances nominated on or after January 7, 2025, into these categories.
Biologics are out of scope
FDA states that biological products aren't eligible for the 503A or 503B compounding exemptions (FDA). Whether a given molecule is regulated as a drug or a biologic matters, so confirm it with your pharmacy partner.
Ask for documentation
Because the statute requires a valid COA for each bulk drug substance from an FDA-registered establishment, a well-run 503A partner should be able to describe its API sourcing and testing. Our guide to choosing a wholesale peptide supplier covers what a good COA and endotoxin report should include.
How 503A affects your clinic's workflow
- Prescriptions come first. Expect patient-specific prescriptions written by a practitioner authorized by state law to prescribe. For who that can include, see who can prescribe peptides.
- Shipping may be direct-to-patient. Many 503A pharmacies dispense to the patient on the prescription. Check your state's rules on dispensing and shipping into the patient's state.
- Handling still matters. Once product arrives, storage and reconstitution practices protect integrity. See our lyophilized peptides storage guide and lyophilized vs. non-lyophilized peptides.
This article is general education, not legal advice. State pharmacy and medical boards add their own rules on top of federal law, so confirm requirements with counsel or your state board.
Work with Biomed Peptides
Biomed Peptides works exclusively with licensed medical practices, med spas, and clinics, with 503A compounding pharmacy partners for patient-specific orders. See how our 503A compounding works, or apply for a provider account.
FAQ
What is a 503A pharmacy?
A 503A pharmacy is a state-licensed pharmacy or federal facility that compounds drugs for identified individual patients based on valid prescriptions, under section 503A of the FD&C Act (21 U.S.C. § 353a). State boards of pharmacy are its primary regulators.
What is the difference between 503A and 503B compounding pharmacies?
503A pharmacies compound against patient-specific prescriptions, aren't subject to CGMP, and are mainly overseen by state boards of pharmacy. 503B outsourcing facilities voluntarily register with FDA, must follow CGMP, are inspected by FDA on a risk-based schedule, and may supply office stock not tied to a named patient.
Can a 503A pharmacy provide office-use stock?
Generally, no. 503A compounding is tied to a valid prescription for an identified individual patient, with only limited anticipatory compounding based on prescription history. Non-patient-specific office stock is the role of 503B outsourcing facilities.
Can 503A compounding pharmacies compound peptides?
They can compound a peptide only if its bulk drug substance meets 503A conditions: a USP or NF monograph, a component of an FDA-approved drug, or inclusion on FDA's 503A bulks list. The substance also has to come from an FDA-registered establishment with a valid certificate of analysis. Check FDA's current pages for each substance's status.
Are 503A compounded drugs FDA-approved?
No. Compounded drugs, whether from 503A or 503B compounders, aren't FDA-approved, so FDA doesn't review their safety, effectiveness, or quality before they're marketed.
Who inspects 503A pharmacies?
State boards of pharmacy have primary responsibility for day-to-day oversight of state-licensed pharmacies that aren't registered as outsourcing facilities. FDA can also conduct surveillance and for-cause inspections.
Sources
- U.S. Food and Drug Administration. Human Drug Compounding Laws. https://www.fda.gov/drugs/human-drug-compounding/compounding-laws-and-policies
- 21 U.S.C. § 353a, Pharmacy compounding (FD&C Act § 503A). Legal Information Institute. https://www.law.cornell.edu/uscode/text/21/353a
- 21 U.S.C. § 353b, Outsourcing facilities (FD&C Act § 503B). Legal Information Institute. https://www.law.cornell.edu/uscode/text/21/353b
- FDA. Bulk Drug Substances Used in Compounding Under Section 503A of the FD&C Act. https://www.fda.gov/drugs/human-drug-compounding/bulk-drug-substances-used-compounding-under-section-503a-fdc-act
- FDA. Information for Outsourcing Facilities. https://www.fda.gov/drugs/human-drug-compounding/information-outsourcing-facilities
- FDA. Registered Outsourcing Facilities. https://www.fda.gov/drugs/human-drug-compounding/registered-outsourcing-facilities
- FDA. Compounding and the FDA: Questions and Answers. https://www.fda.gov/drugs/human-drug-compounding/compounding-and-fda-questions-and-answers
Suggested FAQPage schema (JSON-LD)
<script type="application/ld+json">
{
"@context": "https://schema.org",
"@type": "FAQPage",
"mainEntity": [
{
"@type": "Question",
"name": "What is a 503A pharmacy?",
"acceptedAnswer": {
"@type": "Answer",
"text": "A 503A pharmacy is a state-licensed pharmacy or federal facility that compounds drugs for identified individual patients based on valid prescriptions, under section 503A of the FD&C Act (21 U.S.C. § 353a). State boards of pharmacy are its primary regulators."
}
},
{
"@type": "Question",
"name": "What is the difference between 503A and 503B compounding pharmacies?",
"acceptedAnswer": {
"@type": "Answer",
"text": "503A pharmacies compound against patient-specific prescriptions, aren't subject to CGMP, and are mainly overseen by state boards of pharmacy. 503B outsourcing facilities voluntarily register with FDA, must follow CGMP, are inspected by FDA on a risk-based schedule, and may supply office stock not tied to a named patient."
}
},
{
"@type": "Question",
"name": "Can a 503A pharmacy provide office-use stock?",
"acceptedAnswer": {
"@type": "Answer",
"text": "Generally, no. 503A compounding is tied to a valid prescription for an identified individual patient, with only limited anticipatory compounding based on prescription history. Non-patient-specific office stock is the role of 503B outsourcing facilities."
}
},
{
"@type": "Question",
"name": "Can 503A compounding pharmacies compound peptides?",
"acceptedAnswer": {
"@type": "Answer",
"text": "They can compound a peptide only if its bulk drug substance meets 503A conditions: a USP or NF monograph, a component of an FDA-approved drug, or inclusion on FDA's 503A bulks list. The substance also has to come from an FDA-registered establishment with a valid certificate of analysis. Check FDA's current pages for each substance's status."
}
},
{
"@type": "Question",
"name": "Are 503A compounded drugs FDA-approved?",
"acceptedAnswer": {
"@type": "Answer",
"text": "No. Compounded drugs, whether from 503A or 503B compounders, aren't FDA-approved, so FDA doesn't review their safety, effectiveness, or quality before they're marketed."
}
},
{
"@type": "Question",
"name": "Who inspects 503A pharmacies?",
"acceptedAnswer": {
"@type": "Answer",
"text": "State boards of pharmacy have primary responsibility for day-to-day oversight of state-licensed pharmacies that aren't registered as outsourcing facilities. FDA can also conduct surveillance and for-cause inspections."
}
}
]
}
</script>
Frequently Asked Questions
Quick answers related to this article.